Rosiglitazone Is Associated with Sharp Lipid Irregularity

Published Online: Saturday, January 1, 2005

Researchers in the United Kingdom found 3 cases linking lipid abnormalities with rosiglitazone. The study showed that treatment with rosiglitazone might cause an acute decrease in high-density lipoprotein (HDL; "good") cholesterol and an increase in fasting triglycerides. Reporting in Diabetes Care (November 2004), the researchers said that the 3 participants had type 2 diabetes and high cholesterol and were being treated with rosiglitazone. The results of the study indicated that rosiglitazone was temporally related to a drastic decline in HDL cholesterol.

Once the drug was stopped, the patients had a rapid return of HDL cholesterol to pretreatment levels. All 3 patients had a "striking improvement" in blood sugar control with rosiglitazone treatment even with the abnormal cholesterol response. The researchers noted that the mechanism of rosiglitazone-induced cholesterol abnormalities remains to be determined. Although the cholesterol problem was rare, the researchers recommended that a full lipid profile, including HDL cholesterol, be taken prior to beginning rosiglitazone and similar drugs and again 3 months later.

Latest Articles
A pharmacy robber not only left his fingerprints behind at a pharmacy—he also dropped his wallet containing his identification as he made his escape.
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Treating chronic pulmonary obstructive disease with both inhaled corticosteroids and long-acting bronchodilators remains controversial, but new evidence suggests that this controller combination could reduce mortality risk.
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Latest Issues